Expression of CD30 and CD30L in Human Lymphoid Hematopoietic Malignancies
| Diagnosis . | CD30 . | CD30L . | ||
|---|---|---|---|---|
| . | No. Positive/No. Tested . | % Stained Cells (range)* . | No. Positive/No. Tested . | % Stained Cells (range) . |
| B-cell tumors | 6/93 | 22-26† | 61/93 | 22-94 |
| B-lineage ALL | 0/11 | — | 6/11 | 38-94 |
| B-CLL | 0/47 | — | 33/47 | 22-35 |
| B-PLL | 0/3 | — | 1/3 | 27 |
| HCL | 0/7 | — | 6/7 | 45-79 |
| B-NHL HG | 3/9 | 22-25 | 5/9 | 39-85 |
| LG | 0/9 | — | 6/9 | 25-37 |
| MM | 3/7 | 23-26 | 4/7‡ | 30-45 |
| T-cell tumors | 0/16 | — | 4/16 | 35-56 |
| T-ALL | 0/10 | — | 0/10 | — |
| T-PLL | 0/2 | — | 1/2 | 46 |
| T-NHL HG | 0/1 | — | 0/1 | — |
| LG | 0/1 | — | 1/1 | 35 |
| ATLL | 0/2 | — | 2/2 | 45-56 |
| Diagnosis . | CD30 . | CD30L . | ||
|---|---|---|---|---|
| . | No. Positive/No. Tested . | % Stained Cells (range)* . | No. Positive/No. Tested . | % Stained Cells (range) . |
| B-cell tumors | 6/93 | 22-26† | 61/93 | 22-94 |
| B-lineage ALL | 0/11 | — | 6/11 | 38-94 |
| B-CLL | 0/47 | — | 33/47 | 22-35 |
| B-PLL | 0/3 | — | 1/3 | 27 |
| HCL | 0/7 | — | 6/7 | 45-79 |
| B-NHL HG | 3/9 | 22-25 | 5/9 | 39-85 |
| LG | 0/9 | — | 6/9 | 25-37 |
| MM | 3/7 | 23-26 | 4/7‡ | 30-45 |
| T-cell tumors | 0/16 | — | 4/16 | 35-56 |
| T-ALL | 0/10 | — | 0/10 | — |
| T-PLL | 0/2 | — | 1/2 | 46 |
| T-NHL HG | 0/1 | — | 0/1 | — |
| LG | 0/1 | — | 1/1 | 35 |
| ATLL | 0/2 | — | 2/2 | 45-56 |
CD30 and CD30L expression was evaluated by RT-PCR and immunofluorescence staining using the anti-CD30 MoAb M44 or the anti-CD30L MoAb M80.
Abbreviations: ALL, acute lymphoblastic leukemia; CLL, chronic lymphoblastic leukemia; PLL, prolymphocytic leukemia; HCL, hairy cell leukemia; NHL, non-Hodgkin's lymphoma; HG, high grade; LG, low grade; MM, multiple myeloma; ATLL, adult T-cell leukemia lymphoma.
As evaluated by flow cytometry.
Figures refer to positive cases, ie, displaying more than 20% of stained cells in flow cytometry.
Two cases coexpressed CD30 as evaluated by both RT-PCR and flow cytometry.